profile

Neurology Hero

Neuromodulation Demonstrates Efficacy in Drug-Resistant Focal Epilepsy

Published about 1 month agoΒ β€’Β 2 min read

​

​

⚑ Neuromodulation Device Demonstrates Long-Term Efficacy in Drug-Resistant Focal Epilepsy

A recent study highlights the sustained effectiveness of a neuromodulation device in treating individuals with drug-resistant focal epilepsy over a three-year period. The device, designed to deliver targeted electrical stimulation to specific brain regions, has shown promise in reducing seizure frequency among patients unresponsive to traditional pharmacological treatments.

​

πŸ” Key Findings:

​
Significant Seizure Reduction: Patients utilizing the neuromodulation device experienced a notable decrease in seizure occurrences, indicating its potential as a viable alternative for those with limited treatment options.

Enhanced Quality of Life: Beyond seizure control, many participants reported improvements in daily functioning and overall well-being, underscoring the device's broader impact on patient health.

Durable Outcomes: The therapeutic benefits observed were maintained throughout the three-year study duration, suggesting long-term efficacy of the intervention.

1. ⚑ Responsive Neurostimulation (RNS): Mechanism and Clinical Use

RNS systems deliver targeted stimulation in response to detected abnormal brain activity, interrupting seizures in real time. Understanding how this differs from continuous stimulation (as in deep brain stimulation) helps neurologists tailor treatment for focal epilepsy patients with identifiable seizure foci.

2. πŸ’Š Current Treatment Pathways for Drug-Resistant Epilepsy

When two or more anti-seizure medications fail, patients are considered drug-resistant. Neurologists typically consider options like surgical resection, vagus nerve stimulation (VNS), or RNS β€” making it essential to understand where neuromodulation fits in the surgical vs. device-based treatment decision tree.

3. 🧠 Focal Epilepsy: Localization and Mapping for Neuromodulation

Accurate localization of seizure onset zones using tools like intracranial EEG (iEEG), MEG, or SEEG is critical before implanting responsive devices. Neurologists working with surgical teams must understand how to interpret mapping data to guide optimal electrode placement.

4. πŸ“‰ Long-Term Outcomes and Quality-of-Life Improvements with RNS

Beyond seizure frequency, metrics like neurocognitive function, mood, and patient-reported quality of life are essential to evaluating treatment success. Many patients experience sustained improvements over years, reinforcing RNS as a chronic management tool rather than just acute intervention.

5. πŸ”‹ Device Selection and Programming Considerations in Clinical Practice

Neurologists should be familiar with device capabilities, stimulation parameters, and remote monitoring tools. Adjustments to therapy are data-driven, requiring continuous interpretation of ECoG recordings and responsiveness to patient feedback on symptom changes.

πŸ“š References

  1. Jobst, B. C., & Cascino, G. D. (2015). Resective epilepsy surgery for drug-resistant focal epilepsy: a review.JAMA, 313(3), 285–293.
  2. Heck, C. N., et al. (2014). Two-year seizure reduction in adults with medically intractable partial onset seizures treated with responsive neurostimulation: Final results of the RNS System Pivotal trial.Epilepsia, 55(3), 432–441.
  3. Morrell, M. J. (2011). Responsive cortical stimulation for the treatment of medically intractable partial epilepsy.Neurology, 77(13), 1295–1304.
  4. Geller, E. B., et al. (2017). Brain-responsive neurostimulation in patients with medically intractable mesial temporal lobe epilepsy.Epilepsia, 58(6), 994–1004.
  5. Fisher, R. S., et al. (2021). Seizure diaries and patient-reported outcomes in epilepsy clinical trials: Relevance, limitations, and recommendations.Epilepsia, 62(7), 1582–1591.
  6. Lhatoo, S. D., et al. (2019). The value of intracranial EEG in the evaluation of drug-resistant epilepsy.Nature Reviews Neurology, 15(5), 267–282.
  7. Bergey, G. K., et al. (2015). Long-term treatment with responsive brain stimulation in adults with refractory partial seizures.Neurology, 84(8), 810–817.
  8. Fisher, R. S., et al. (2017). Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology.Epilepsia, 58(4), 522–530.
  9. Skarpaas, T. L., et al. (2019). Programming and optimizing responsive neurostimulation therapy for epilepsy.Epilepsy & Behavior, 91, 68–74.
  10. Engel, J. Jr. (2018). Surgical treatment for epilepsy: Too little, too late?JAMA Neurology, 75(6), 579–580.

​

Neurology Hero

Deep Dives in Neurology and Neuroscience Updates

Read more from Neurology Hero

🧬 AMX0035 Shows Sustained Benefit in Wolfram Syndrome at 48 Weeks Amylyx Pharmaceuticals has reported positive long-term results from its Phase 2 HELIOS trial evaluating AMX0035 in individuals with Wolfram syndrome, a rare, progressive neurodegenerative disease. At 48 weeks, the treatment continued to demonstrate improvements or stabilization across multiple disease domains, suggesting durable therapeutic benefit. πŸ” Key Highlights Pancreatic Function: C-peptide responseβ€”a marker of residual...

10 days agoΒ β€’Β 2 min read

πŸ’€ Oral Therapy AD109 Shows Promise in Treating Obstructive Sleep Apnea A recent phase 3 clinical trial has shown that AD109, an investigational oral therapy, significantly reduces the severity of obstructive sleep apnea (OSA) over a six-month period. The SynAIRgy study focused on adults with mild to severe OSA who were either intolerant of or declined CPAP therapy. πŸ” Key Findings Marked Reduction in AHI: Participants receiving AD109 experienced a 55.6% decrease in apnea-hypopnea index (AHI),...

about 1 month agoΒ β€’Β 2 min read

🧠 Semaglutide’s Appetite-Suppressing Effects Traced to Brainstem Neurons A new study in Cell Metabolism reveals how semaglutide, a GLP-1 receptor agonist, suppresses appetite and drives weight loss through a specific set of neurons in the brainstem. The findings help explain the neural basis behind one of the most effective anti-obesity medications currently in clinical use. πŸ” Key Highlights Brainstem Circuit Activation: Researchers identified a population of neurons expressing the Adcyap1...

about 1 month agoΒ β€’Β 2 min read